http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2011021381-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 |
| filingDate | 2010-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2011021381-A1 |
| titleOfInvention | Pharmaceutical composition comprising anti-HB-EGF antibody as an active ingredient |
| abstract | Disclosed are anti-HB-EGF antibodies having internalizing activity. Preferably, a cytotoxic substance is bound to the anti-HB-EGF antibody of the present invention. Also provided are a cancer therapeutic agent and cell growth inhibitor containing the antibody of the present invention as an active ingredient, and a cancer treatment method and diagnostic method characterized by administering the antibody of the present invention. Cancers that can be treated with the cancer therapeutic agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colon cancer, gastric cancer, ovarian cancer, cervical cancer, breast cancer, bladder cancer, brain tumor or blood cancer. |
| priorityDate | 2009-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1326.